top of page
News, Events and Updates
Search
Mar 25, 2024
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Mar 18, 2024
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Feb 26, 2024
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
Feb 7, 2024
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
Feb 1, 2024
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Jan 24, 2024
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humans
Jan 16, 2024
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Jan 8, 2024
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
Jan 3, 2024
Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Jan 2, 2024
Anavex Life Sciences Provides an Update on Rett Syndrome Program
Dec 20, 2023
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
1
2
3
4
5
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
